Release open label data from nomlabofusp study

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 14 Aug 2025
Due: 30 Sep 2025
Delivered: September 2025

Deadline
Met
Late
Not met
Today

What the company said

“Open label data from 30-40 participants who received at least one dose of nomlabofusp, including subjects on 50 mg dose, expected Sept 2025.”

SourceLarimar Therapeutics, Inc. Form 8-K press release, 2025-08-14
FilingSEC filing index
Deadline as statedSept 2025
Deadline used30 Sep 2025, the last day of the stated period
TypeProject
Permanent referenceKI-C-2025-LRMR-003063
Cite as https://keptindex.org/c/KI-C-2025-LRMR-003063/ — this address never changes.

What we found

Evidence strength A What the grades mean

Larimar Therapeutics announced open label data for nomlabofusp in September 2025, confirming that 39 participants had been dosed in the open label study, meeting the commitment.

A
Larimar Therapeutics, Inc. 10-Q filed 2025-11-05 Regulatory filing · published 5 Nov 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In September 2025, the Company announced data from its ongoing long-term open label study: o In four completed studies and its ongoing open label study, 65 participants received at least one dose of nomlabofusp, including 39 in the open label study” ✓ confirmed on the page

Market reaction: the shares moved -8.3% against the S&P 500 over the three sessions around the disclosure (4 Nov 2025 to 7 Nov 2025). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +273 days
2 versions

Version 1 · original · stated 14 Aug 2025

Deadline 30 Sep 2025 (“Sept 2025”) · target 30 participants · wording expected
Version 2 · stated 24 Feb 2026

Deadline 30 Jun 2026 (“Q2 2026”) · wording expected

“Topline open label study data to support BLA submission expected in Q2 2026”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Release
Deliverable: Open label data
Target: 30 participants
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.